Zhang Changsong, Guo Xianling, Jiang Guocheng, Zhang Li, Yang Yang, Shen Feng, Wu Mengchao, Wei Lixin
Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, the Second Military Medical University, Shanghai, China.
Int J Cancer. 2008 Sep 1;123(5):998-1004. doi: 10.1002/ijc.23650.
CpG island methylator phenotype (CIMP) involves the targeting of multiple genes by promoter hypermethylation. Telomerase plays an important role in the development of cellular immortality and oncogenesis. To gain insight into the role of epigenetic aberration of telomerase-related genes in hepatocarcinogenesis, we determined a hypermethylation profile in HCC. We examined the promoter methylation status of 9 genes associated with telomerase activity in 120 HCC, 120 cirrhosis tissues and 10 normal liver tissues by methylation-specific PCR. Assay of telomerase activity was by TRAP-ELISA. The frequency of promoter methylation of each gene was P21 63.3%, P15 42.5%, P16 62.5%, P53 14.2%, RB 32.5%, P27 48.3%, WTI 54.2%, E2F-1 70.8% and P300 65.8% of 120 HCC. Methylation status of P21, P15, P16, WTI and E2F-1 was significantly associated with HCC and nontumor tissues (p < 0.05). CIMP+ was detected in 61.7% (74/120) HCC and 15% (18/120) cirrhosis tissues, no CIMP+ was present in normal liver tissues (p < 0.001). A significant difference between CIMP status and metastasis was been found in HCC (p < 0.001). Results showed that 94.6% (70/74) HCC and 55.6% (10/18) cirrhosis patients with CIMP+ show expression of high telomerase activity than 45.5% (10/22) HCC and 6.25% (1/16) cirrhosis patients with CIMP- (p < 0.001). CIMP lead to high levels of expression of telomerase activity through the simultaneous inactivation of multiple genes associated with telomerase activity by concordant methylation.
CpG岛甲基化表型(CIMP)涉及通过启动子高甲基化对多个基因进行靶向作用。端粒酶在细胞永生化和肿瘤发生发展中起重要作用。为深入了解端粒酶相关基因的表观遗传异常在肝癌发生中的作用,我们确定了肝癌中的高甲基化谱。我们通过甲基化特异性PCR检测了120例肝癌、120例肝硬化组织和10例正常肝组织中9个与端粒酶活性相关基因的启动子甲基化状态。端粒酶活性检测采用TRAP-ELISA法。120例肝癌中各基因启动子甲基化频率分别为:P21 63.3%、P15 42.5%、P16 62.5%、P53 14.2%、RB 32.5%、P27 48.3%、WT1 54.2%、E2F-1 70.8%和P300 65.8%。P21、P15、P16、WT1和E2F-1的甲基化状态与肝癌及非肿瘤组织显著相关(p<0.05)。在61.7%(74/120)的肝癌和15%(18/120)的肝硬化组织中检测到CIMP+,正常肝组织中未检测到CIMP+(p<0.001)。在肝癌中发现CIMP状态与转移之间存在显著差异(p<0.001)。结果显示,CIMP+的肝癌患者中94.6%(70/74)和肝硬化患者中55.6%(10/18)的端粒酶活性表达高于CIMP-的肝癌患者中45.5%(10/22)和肝硬化患者中6.25%(1/16)(p<0.001)。CIMP通过协同甲基化同时使多个与端粒酶活性相关的基因失活,导致端粒酶活性表达水平升高。